Oxaliplatin and Haematotoxicity - a phase IV clinical study of FDA data

Summary:

Haematotoxicity is reported as a side effect among people who take Oxaliplatin (oxaliplatin), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Fluorouracil, and have Colorectal cancer metastatic.

The phase IV clinical study analyzes which people have Haematotoxicity when taking Oxaliplatin. It is created by eHealthMe based on reports of 71,972 people who have side effects when taking Oxaliplatin from the FDA, and is updated regularly.

What is Oxaliplatin?

Oxaliplatin has active ingredients of oxaliplatin. It is often used in colon cancer. eHealthMe is studying from 72,058 Oxaliplatin users. Check the latest studies of Oxaliplatin.

What is Haematotoxicity?

Haematotoxicity (toxins that destroy red blood cells) is found to be associated with 343 drugs and 830 conditions by eHealthMe. Check the latest studies of Haematotoxicity.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

71,972 people reported to have side effects when taking Oxaliplatin.
Among them, 607 people (0.84%) have Haematotoxicity.

Could Oxaliplatin cause Haematotoxicity?

Among these 607 people:

How long have people been on Oxaliplatin when they have Haematotoxicity? *

Click here to view more results

What is the gender of people who have Haematotoxicity when taking Oxaliplatin? *

Click here to view

* Approximation only. Some reports may have incomplete information.

Do you take Oxaliplatin and have Haematotoxicity?

- Check whether Haematotoxicity is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Oxaliplatin:

Oxaliplatin (72,058 reports)

Haematotoxicity treatments and more:

Haematotoxicity (8,984 reports)

How severe was Haematotoxicity and when was it recovered:

Haematotoxicity in Oxaliplatin

Expand to all the drugs that have ingredients of oxaliplatin:

Haematotoxicity and drugs with ingredients of oxaliplatin (614 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Oxaliplatin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Haematotoxicity:

Haematotoxicity (343 drugs)

Browse all the conditions that are associated with Haematotoxicity:

Haematotoxicity (830 conditions)

Related publications that referenced our studies

Kim HJ, An SH, Cho YH, Kim SY, Lee HG, Yoon SY, "Oxaliplatin-induced Torsades de pointes and long QT syndrome in a patient with gastric cancer", Acta Oncologica, 2013 Aug .
Wang JH, King TM, Chang MC, Hsu CW, "Oxaliplatin-induced severe anaphylactic reactions in metastatic colorectal cancer: case series analysis", World journal of gastroenterology: WJG, 2012 Oct .
Kim HJ, An SH, Cho YH, Kim SY, Lee HG, Yoon SY, "Oxaliplatin-induced Torsades de pointes and long QT syndrome in a patient with gastric cancer", Acta Oncologica, 2013 Aug .
Wang JH, King TM, Chang MC, Hsu CW, "Oxaliplatin-induced severe anaphylactic reactions in metastatic colorectal cancer: case series analysis", World journal of gastroenterology: WJG, 2012 Oct .

How the study uses the data?

The study uses data from the FDA. It is based on oxaliplatin (the active ingredients of Oxaliplatin) and Oxaliplatin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.